CVRX News and Press, CVRx Inc. From 06/22/23

MINNEAPOLIS, June 22, 2023 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, today announced that ...

2023-06-17 13:00:00 ET Summary CVRx's stock price has risen 38% following the BeAT-HF trial readouts, with potential catalysts for further growth, including Barostim and sentiment factors. The company is in interactive discussions with the FDA to expand Barostim's label to treat h...

2023-06-16 16:40:37 ET Summary I called CVRx a highly risky but potentially lucrative investment at the time of the IPO in the summer of 2021. The company has seen solid revenue growth ever since, although accompanied by substantial losses. Missing the primary endpoint in the ...

MINNEAPOLIS, May 25, 2023 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, today announced that t...

2023-04-29 22:21:05 ET CVRx, Inc. (CVRX) Q1 2023 Earnings Conference Call April 27, 2023 17:00 ET Company Participants Michael Vallie - Investor Relations Nadim Yared - President and Chief Executive Officer Jared Oasheim - Chief Financial Officer Conference...

2023-04-28 10:03:38 ET Gainers: Tempest Therapeutics ( TPST ) +72% . CVRx ( CVRX ) +25% . ImmunoGen ( IMGN ) +22% . Apyx Medical ( APYX ) +17% . bluebird bio ( BLUE ) +17% . Losers: Hillstream BioPharma ( HILS ) -56%...

2023-04-27 16:46:09 ET CVRx press release ( NASDAQ: CVRX ): Q1 GAAP EPS of -$0.55 beats by $0.02 . Revenue of $8M (+96.1% Y/Y) beats by $0.79M . For further details see: CVRx GAAP EPS of -$0.55 beats by $0.02, revenue of $8M beats by $0.79M

MINNEAPOLIS, April 27, 2023 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, today announced its ...

MINNEAPOLIS, April 20, 2023 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing and commercializing Barostim™, an innovative extravascular implantable neuromodulation device for patients with c...

MINNEAPOLIS, March 21, 2023 (GLOBE NEWSWIRE) -- CVRx, Inc . (NASDAQ: CVRX) (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing and commercializing Barostim™, an innovative extravascular implantable neuromodulation device for patien...